SG11201506479TA - Substituted xanthines and methods of use thereof - Google Patents

Substituted xanthines and methods of use thereof

Info

Publication number: SG11201506479TA
Authority: SG; Singapore
Prior art keywords: methods; substituted xanthines; xanthines; substituted
Prior art date: 2013-03-15

Application number

SG11201506479TA

Other languages

English (en)

Inventor

Bertrand Chenard

Randall Gallaschun

Original Assignee

Hydra Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2015-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506479T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc

2015-09-29 Publication of SG11201506479TA publication Critical patent/SG11201506479TA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

SG11201506479TA 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof SG11201506479TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361789724P	2013-03-15	2013-03-15
PCT/US2014/027920 WO2014143799A2 (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof

Publications (1)

Publication Number	Publication Date
SG11201506479TA true SG11201506479TA (en)	2015-09-29

Family

ID=50680155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201506479TA SG11201506479TA (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof

Country Status (32)

Country	Link
US (6)	US9359359B2 (hr)
EP (1)	EP2970303B3 (hr)
JP (1)	JP6360149B2 (hr)
KR (1)	KR102227629B1 (hr)
CN (2)	CN105143229B (hr)
AU (1)	AU2014228206C1 (hr)
CA (1)	CA2899646C (hr)
CL (1)	CL2015002738A1 (hr)
CY (1)	CY1119042T1 (hr)
DK (1)	DK2970303T6 (hr)
EA (1)	EA028815B1 (hr)
ES (1)	ES2636835T7 (hr)
HK (1)	HK1217329A1 (hr)
HR (1)	HRP20170840T4 (hr)
HU (1)	HUE033528T4 (hr)
IL (1)	IL240216B (hr)
LT (1)	LT2970303T (hr)
MX (1)	MX370372B (hr)
MY (1)	MY189912A (hr)
NZ (1)	NZ711718A (hr)
PE (1)	PE20151779A1 (hr)
PH (1)	PH12015502141B1 (hr)
PL (1)	PL2970303T6 (hr)
PT (1)	PT2970303T (hr)
RS (1)	RS56066B2 (hr)
SG (1)	SG11201506479TA (hr)
SI (1)	SI2970303T1 (hr)
TW (1)	TWI609867B (hr)
UA (1)	UA117470C2 (hr)
UY (1)	UY35488A (hr)
WO (1)	WO2014143799A2 (hr)
ZA (1)	ZA201505414B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173750B2 (en)	2009-04-23	2012-05-08	ATRP Solutions, Inc.	Star macromolecules for personal and home care
JP6360149B2 (ja)	2013-03-15	2018-07-18	ハイドラバイオサイエンシズインコーポレイテッドＨｙｄｒａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	置換キサンチンおよびその使用方法
WO2016023831A1 (en) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016159746A1 (en)	2015-03-27	2016-10-06	Latvian Institute Of Organic Synthesis	Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
GB2553686B (en)	2015-03-27	2020-06-03	Latvian Inst Organic Synthesis	Ethynylxanthines, preparation and use as calcium ion channel modulators
GB2553684B (en)	2015-03-27	2020-06-03	Latvian Inst Organic Synthesis	Ethynylxanthines, preparation and use for cancer treatment
PL3280417T3 (pl) *	2015-04-08	2020-12-28	Lewis And Clark Pharmaceuticals, Inc.	Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub>
CN107118586A (zh) *	2016-02-24	2017-09-01	中国科学技术大学	含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) *	2017-02-09	2017-03-29	Univ Leeds Innovations Ltd	Inhibitors for use in therapy
US11666577B2 (en) *	2017-02-28	2023-06-06	National Institute Of Biological Sciences, Beijing	MLKL inhibitors
CN110573509B (zh) *	2017-02-28	2023-05-26	北京生命科学研究所	Mlkl抑制剂
SI3652176T1 (sl) *	2017-07-11	2022-04-29	Boehringer Ingelheim International Gmbh	Substituirani ksantinski derivati
CA3093084A1 (en)	2018-03-05	2019-09-12	Goldfinch Bio, Inc.	Imidazodiazepinediones and methods of use thereof
CN113166150B (zh) *	2018-12-12	2023-12-01	勃林格殷格翰国际有限公司	经取代的黄嘌呤衍生物
KR20210102955A (ko)	2018-12-12	2021-08-20	베링거 인겔하임 인터내셔날 게엠베하	치환된 크산틴 유도체
CN112979651B (zh) *	2021-04-09	2022-02-01	南京纽邦生物科技有限公司	一种副黄嘌呤的制备方法
CN113354646B (zh) *	2021-07-06	2022-11-15	南开大学	8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831A (zh) *	2022-10-27	2023-01-24	中国药科大学	稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4304650A1 (de) *	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja)	1996-05-17	2008-12-03	興和株式会社	新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja)	1997-05-16	1998-12-04	Mitsubishi Gas Chem Co Inc	真空断熱材用ゲッタ
US6075029A (en) *	1998-01-02	2000-06-13	Cell Therapeutics, Inc.	Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) *	1998-04-16	2001-02-13	Boehringer Ingelheim Pharma Kg	Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
CA2369981A1 (en) *	1999-04-09	2000-10-19	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
IL153182A0 (en) *	2000-07-04	2003-06-24	Novo Nordisk As	Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
CA2430951A1 (en)	2000-12-07	2002-06-13	Cv Therapeutics, Inc.	Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
NZ528216A (en) *	2001-02-24	2006-12-22	Boehringer Ingelheim Pharma	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
AU2002359365B2 (en) *	2001-11-09	2008-07-10	Gilead Sciences, Inc.	A2B adenosine receptor antagonists
DE60322748D1 (de) *	2003-05-06	2008-09-18	Cv Therapeutics Inc	Xanthinderivate als a2b-adenosinrezeptorantagonisten
CA2545944A1 (en)	2003-11-13	2005-06-02	Board Of Regents, The University Of Texas System	Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
WO2006074051A2 (en)	2004-12-30	2006-07-13	Diakine Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2006089168A2 (en)	2005-02-18	2006-08-24	Cornell Research Foundation, Inc.	Methods for modulating ion channels
NZ565494A (en) *	2005-08-10	2011-06-30	Glaxosmithkline Llc	Xanthine derivatives as selective HM74A agonists
WO2007030359A1 (en)	2005-09-06	2007-03-15	Smithkline Beecham Corporation	Benzimidazole thiophene compounds as plk modulators
JP2009518333A (ja) *	2005-12-07	2009-05-07	ユセベファルマソシエテアノニム	キサンチン誘導体、その調製方法及びその使用
TWI423819B (zh) *	2005-12-22	2014-01-21	Hydra Biosciences Inc	用於調節ｔｒｐａ１功能之化合物
EP1983992A4 (en)	2006-01-19	2010-08-18	Abbott Lab	2-IMINO-BENZIMIDAZOLES
WO2007101213A2 (en)	2006-02-28	2007-09-07	Kalypsys, Inc.	Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) *	2006-07-19	2008-01-24	Diakine Therapeutics, Inc.	Encapsulation system
WO2009157938A1 (en) *	2008-06-26	2009-12-30	Cv Therapeutics, Inc.	A2b adenosine receptor antagonists for treating cancer
WO2011022638A1 (en)	2009-08-20	2011-02-24	Transposagen Biopharmaceuticals, Inc.	Trp inhibitors and uses thereof
WO2011114184A1 (en) *	2010-03-15	2011-09-22	Glenmark Pharmaceuticals S.A.	Amides of heterocyclic compounds as trpa1 inhibitors
US9260430B2 (en)	2010-06-08	2016-02-16	Hydra Biosciences, Inc.	Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) *	2011-07-22	2013-02-04	Panasonic Corp	列車情報提供システム
TW201311690A (zh) *	2011-08-09	2013-03-16	Hydra Biosciences Inc	抑制暫態受體電位離子通道ｔｒｐａ１
CN103121970B (zh)	2012-12-04	2015-04-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
JP6360149B2 (ja)	2013-03-15	2018-07-18	ハイドラバイオサイエンシズインコーポレイテッドＨｙｄｒａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	置換キサンチンおよびその使用方法

2014
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active IP Right Grant
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
- 2016-05-10 HK HK16105298.0A patent/HK1217329A1/zh unknown
2017
- 2017-06-01 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active

Also Published As

Publication number	Publication date
US20160237089A1 (en)	2016-08-18
ES2636835T7 (es)	2018-11-20
AU2014228206C1 (en)	2018-10-25
IL240216B (en)	2018-11-29
MX370372B (es)	2019-12-11
UA117470C2 (uk)	2018-08-10
KR102227629B1 (ko)	2021-03-16
PE20151779A1 (es)	2015-11-20
RS56066B2 (sr)	2018-09-28
CN105143229B (zh)	2017-06-30
NZ711718A (en)	2020-05-29
KR20150133233A (ko)	2015-11-27
EP2970303A2 (en)	2016-01-20
HRP20170840T1 (hr)	2017-09-08
EA028815B1 (ru)	2018-01-31
ZA201505414B (en)	2016-03-30
CN105143229A (zh)	2015-12-09
DK2970303T3 (en)	2017-06-26
JP6360149B2 (ja)	2018-07-18
EA201591615A1 (ru)	2016-05-31
WO2014143799A4 (en)	2015-02-12
CA2899646A1 (en)	2014-09-18
US20140275071A1 (en)	2014-09-18
PL2970303T3 (pl)	2017-08-31
AU2014228206B2 (en)	2018-05-10
LT2970303T (lt)	2017-07-25
HK1217329A1 (zh)	2017-01-06
WO2014143799A9 (en)	2014-12-24
WO2014143799A3 (en)	2014-11-06
UY35488A (es)	2014-10-31
EP2970303B1 (en)	2017-05-10
HUE033528T2 (hu)	2017-12-28
WO2014143799A2 (en)	2014-09-18
US20180244674A1 (en)	2018-08-30
MX2015011617A (es)	2016-04-25
US11958854B2 (en)	2024-04-16
US20190322667A1 (en)	2019-10-24
US9359359B2 (en)	2016-06-07
DK2970303T6 (en)	2018-10-08
DK2970303T5 (en)	2018-01-02
BR112015021164A2 (pt)	2017-07-18
EP2970303B3 (en)	2018-08-01
EP2970303B9 (en)	2017-09-20
PT2970303T (pt)	2017-06-23
US10399982B2 (en)	2019-09-03
US9969736B2 (en)	2018-05-15
US11208409B2 (en)	2021-12-28
HRP20170840T4 (hr)	2018-11-16
ES2636835T3 (es)	2017-10-09
PH12015502141A1 (en)	2016-01-25
MY189912A (en)	2022-03-21
CA2899646C (en)	2021-08-31
IL240216A0 (en)	2015-09-24
CN107082782B (zh)	2020-03-20
HUE033528T4 (en)	2018-05-02
CL2015002738A1 (es)	2016-06-10
PH12015502141B1 (en)	2016-01-25
TWI609867B (zh)	2018-01-01
CY1119042T1 (el)	2018-01-10
JP2016513717A (ja)	2016-05-16
US20170305910A1 (en)	2017-10-26
SI2970303T1 (sl)	2017-08-31
PL2970303T6 (pl)	2018-12-31
US20230040259A1 (en)	2023-02-09
TW201533044A (zh)	2015-09-01
RS56066B1 (sr)	2017-10-31
AU2014228206A1 (en)	2015-09-24
CN107082782A (zh)	2017-08-22
BR112015021164A8 (pt)	2019-12-03

Publication	Publication Date	Title
HRP20170840T1 (hr)	2017-09-08	Supstituirani ksantini i metode njihove uporabe
IL290547A (en)	2022-04-01	Antibodies and methods of use
IL244495A0 (en)	2016-04-21	Anti-alpha-synuclein antibodies and methods of use
GB2535360B (en)	2017-04-12	Methods of preparing polyhemiaminals and polyhexahydrotriazines
SG11201600707QA (en)	2016-02-26	Substituted aminopyrimidine compounds and methods of use
HK1225612A1 (zh)	2017-09-15	抗ly6e抗體及使用方法
HK1224307A1 (zh)	2017-08-18	原毒素- 變體及其使用方法
HK1218247A1 (zh)	2017-02-10	益生菌和使用方法
IL245272A0 (en)	2016-06-30	pif-transfected cells and methods of use